Genetic Testing Yield and Clinical Characteristics of Hypertrophic Cardiomyopathy in Understudied Ethnic Groups: Insights From a New Zealand National Registry
Authors:
- Nikki J. EarleNENikki J. Earle
- Annika WinboAWAnnika Winbo
- Jackie CrawfordJCJackie Crawford
- Miriam WheelerMWMiriam Wheeler
- Tom DonoghueTDTom Donoghue
- Martin K. StilesMSMartin K. Stiles
- Ian HayesIHIan Hayes
- Luciana MarcondesLMLuciana Marcondes
- Andrew MartinAMAndrew Martin
- Jonathan R. SkinnerJSJonathan R. Skinner
Open Access
- 1 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (3) , e010970
Abstract
BACKGROUND: Aotearoa/New Zealand has a multiethnic population. Patients with hypertrophic cardiomyopathy (HCM) are enrolled in the national Cardiac Inherited Diseases Registry New Zealand. Here, we report the characteristics of Cardiac Inherited Diseases Registry New Zealand HCM probands with and without pathogenic or likely pathogenic (P/LP) genetic variants for HCM, and assess genetic testing yield and variant spectrum by self-identified ethnicity. METHODS: Probands with HCM and enrolled in Cardiac Inherited Diseases Registry New Zealand who have undergone clinical genetic testing over a 17-year period were included. Clinical data, family history, and genetic test results were analyzed. RESULTS: Of 336 probands, 121 (36%) were women, 220 (66%) were European ethnicity, 41 (12%) were Māori, 26 (8%) were Pacific people, and 49 (15%) were other ethnicities. Thirteen probands (4%) presented with sudden death and 19 (6%) with cardiac arrest. A total of 134 (40%) had a P/LP variant identified; most commonly in the MYBPC3 gene (60%) followed by the MYH7 gene (24%). A P/LP variant was identified in 27% of Māori or Pacific probands versus 43% European or other ethnicity probands ( P =0.022); 16% of Māori or Pacific probands had a variant of uncertain significance identified, compared with 9% of European or other ethnicity probands ( P =0.092). Women more often had a P/LP variant identified than men (48% versus 35%; P =0.032), and variant-positive probands were younger at clinical diagnosis than variant of uncertain significance/variant-negative probands (39±17 versus 50±17 years; P P =0.002). CONCLUSIONS: Carriage of a P/LP variant in HCM probands is associated with presentation at younger age, and cardiac arrest or sudden death events. Māori or Pacific probands were less likely to have a P/LP variant identified than European or other ethnicity probands.Keywords
This publication has 34 references indexed in Scilit:
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Higher prevalence of left ventricular hypertrophy in two Māori cohorts: findings from the Hauora Manawa/Community Heart StudyAustralian and New Zealand Journal of Public Health, 2015
- Characterization of a Phenotype-Based Genetic Test Prediction Score for Unrelated Patients With Hypertrophic CardiomyopathyMayo Clinic Proceedings, 2014
- Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathyGenetics in Medicine, 2013
- Prevalence and Distribution of Sarcomeric Gene Mutations in Japanese Patients With Familial Hypertrophic CardiomyopathyCirculation Journal, 2012
- Melanesian and Asian Origins of Polynesians: mtDNA and Y Chromosome Gradients Across the PacificMolecular Biology and Evolution, 2006
- Sudden Unexplained DeathCirculation, 2005
- Comprehensive Analysis of the Beta-Myosin Heavy Chain Gene in 389 Unrelated Patients With Hypertrophic CardiomyopathyJACC, 2004
- Review of first 5 years of screening for familial hypercholesterolaemia in the NetherlandsThe Lancet, 2001
- Mapping a Gene for Familial Hypertrophic Cardiomyopathy to Chromosome 14q1New England Journal of Medicine, 1989